X-Chem Announces Achievement of Collaboration Milestone
05 Dec 2023
WALTHAM, Mass.--(BUSINESS WIRE)--X-Chem, a global leader in innovative drug discovery services, announces the achievement of a drug discovery milestone, following a partner’s attainment of a development candidate. Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, utilized X-Chem’s DNA-Encoded Library (DEL) platform to perform hit finding intended to discover molecules with differentiated pharmacological properties. The resulting molecule led to a development candidate — a milestone under the companies’ collaboration agreement and to progress in evaluation.
'Drug discovery leaders @X-ChemInc and @Relay_Tx reach milestone achievement of development candidate.'
“Relay Therapeutics is an incredibly innovative company with a unique approach to drug discovery,” said X-Chem CEO Matt Clark. “We are immensely proud that our collaboration was able to provide a compelling starting point for Relay Therapeutics’ drug discovery campaign that led to a development candidate. We look forward to seeing Relay bring these innovations forward to the benefit of patients.”
About X-Chem
X-Chem, Inc. is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.